AXIM Biotechnologies, Inc. (AXIM) stock
AXIMOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2024, quarter ended Jun 30, 2024Last filing: 10-Q on Aug 19, 2024
$0.00+0.00 (+2.00%)
Close on Oct 19, 2026Market cap –P/E –Yield –
AXIM Biotechnologies operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
AXIM Biotechnologies's operating income for the twelve months ending Jun 30, 2024 was -$2.31M. For fiscal 2023 it was -$2.75M. The highest annual figure on record is -$505.73K in fiscal 2014.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$2.75M | – |
| FY2022 | Dec 31, 2022 | -$4.65M | – |
| FY2021 | Dec 31, 2021 | -$13.97M | – |
| FY2020 | Dec 31, 2020 | -$4.95M | – |
| FY2019 | Dec 31, 2019 | -$3.11M | – |
| FY2018 | Dec 31, 2018 | -$5.04M | – |
| FY2017 | Dec 31, 2017 | -$3.15M | – |
| FY2016 | Dec 31, 2016 | -$3.76M | – |
| FY2015 | Dec 31, 2015 | -$10.05M | – |
| FY2014 | Dec 31, 2014 | -$505.73K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2024 | Jun 30, 2024 | -$569.44K | – |
| Q1 FY2024 | Mar 31, 2024 | -$401.56K | – |
| Q4 FY2023 | Dec 31, 2023 | -$753.94K | – |
| Q3 FY2023 | Sep 30, 2023 | -$588.54K | – |
| Q2 FY2023 | Jun 30, 2023 | -$697.73K | – |
| Q1 FY2023 | Mar 31, 2023 | -$710.63K | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.14M | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.32M | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.06M | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.13M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.65M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.28M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.18M | – |
| Q1 FY2021 | Mar 31, 2021 | -$868.00K | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.26M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.30M | – |
| Q2 FY2020 | Jun 30, 2020 | -$662.86K | – |
| Q1 FY2020 | Mar 31, 2020 | -$688.73K | – |
| Q4 FY2019 | Dec 31, 2019 | -$568.49K | – |
| Q3 FY2019 | Sep 30, 2019 | -$483.67K | – |
| Q2 FY2019 | Jun 30, 2019 | -$583.44K | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.29M | – |
| Q4 FY2018 | Dec 31, 2018 | -$723.12K | – |
| Q3 FY2018 | Sep 30, 2018 | -$935.83K | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.34M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.04M | – |
| Q4 FY2017 | Dec 31, 2017 | -$1.05M | – |
| Q3 FY2017 | Sep 30, 2017 | -$1.19M | – |
| Q2 FY2017 | Jun 30, 2017 | -$437.25K | – |
| Q1 FY2017 | Mar 31, 2017 | -$476.33K | – |
| Q4 FY2016 | Dec 31, 2016 | -$770.22K | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.56M | – |
| Q2 FY2016 | Jun 30, 2016 | -$491.49K | – |
| Q1 FY2016 | Mar 31, 2016 | -$942.18K | – |
| Q4 FY2015 | Dec 31, 2015 | -$6.31M | – |
| Q3 FY2015 | Sep 30, 2015 | -$1.69M | – |
| Q2 FY2015 | Jun 30, 2015 | -$1.56M | – |
| Q1 FY2015 | Mar 31, 2015 | -$488.82K | – |
| Q4 FY2014 | Dec 31, 2014 | -$370.10K | – |
| Q3 FY2014 | Sep 30, 2014 | -$127.94K | – |
See a number that looks wrong?